Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol.

摘要: From June 1990 to February 1996, 35 patients with B-cell acute lymphoblastic leukaemia (B-ALL) 13 of whom had CNS disease and 28 stage IV non-Hodgkin's lymphoma (B-NHL) 22 involvement were treated a short, intensive multiagent chemotherapy regimen (UKCCSG 9003 protocol) based on the French LMB 86 regimen. Fifty-five boys. The age range was 11 months 16.5 years (median 8.4 years). Chemotherapy included cyclophosphamide, vincristine, daunorubicin, high-dose methotrexate (COPADM) etoposide/high-dose cytarabine (CYVE) frequent intrathecal (i.t.) triple therapy (methotrexate, hydrocortisone). Cranial irradiation (24 Gy in 15 fractions) recommended overt disease. One patient Wiskott-Aldrich syndrome withdrawn after entry has been excluded from analysis. Ten (16%) have relapsed (CNS, four; BM, two; combined three; jaw, one) 4-11 diagnosis two never achieved complete remission (CR). All died. In seven who relapsed, treatment modified or delayed because poor clinical condition. Seven (11%) died toxicity days 4 diagnosis. cause death sepsis (n = 5) renal failure 2). With median follow-up 3.1 (range 9 6.3 years), 43 (69%) survive CR. This study confirms effectiveness this regard relapse rate (16%), although toxic is concern.